A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2018
At a glance
- Drugs ABBV 176 (Primary)
- Indications Adrenocortical carcinoma; Breast cancer; Colorectal cancer; Liver cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 20 Jul 2018 Planned number of patients changed from 100 to 120.
- 02 Apr 2018 Planned End Date changed from 3 Sep 2019 to 7 Mar 2020.
- 21 Jul 2017 Planned End Date changed from 9 Jul 2019 to 3 Sep 2019.